QIAGEN Introduces 100 New Assays for Enhanced Digital PCR Solutions

QIAGEN's Latest Expansion of the QIAcuity Portfolio

In an exciting announcement, QIAGEN has expanded its offerings with over 100 new assays for its QIAcuity digital PCR platform. This significant development strengthens their capabilities in various areas, such as cancer research, genetic disorders, infectious disease surveillance, and environmental monitoring. Available through the GeneGlobe platform, these assays integrate cutting-edge technology and extensive biological resources for researchers and healthcare professionals.

Advanced Features of GeneGlobe Platform

The GeneGlobe platform not only houses these new assays but also boasts a comprehensive database featuring over 10,000 biological entities, including genes, miRNAs, and various pathways. This integration allows for enhanced precision and efficiency in molecular diagnostics, supporting scientists with pre-designed assays tailored to their specific research needs.

Continued Growth and Success

In 2024 alone, QIAGEN has surpassed its target by launching more than 130 new assays, contributing to an impressive total of over 2,300 validated assays within its portfolio. Nitin Sood, Senior Vice President at QIAGEN, expressed the company's commitment to meeting customer needs and advancing the capabilities of the QIAcuity platform.

Key Applications and Benefits

The newly introduced assays include powerful options such as:

• dPCR LNA Mutation and dPCR CNV Probe Assays focus on critical cancer-relevant mutations and changes in copy numbers of specific DNA sequences. These are particularly useful for analyzing colorectal cancer, sarcomas, and thyroid cancer.
• dPCR Microbial DNA Detection Assays target critical pathogens associated with infectious diseases, such as urinary tract infections, while also addressing microbial resistance and plant pathogens affecting agriculture.

Strong Market Adoption

The QIAcuity digital PCR system has demonstrated widespread adoption, with over 2,000 installations reported by the end of 2023. This widespread use includes a significant citation presence in more than 450 publications. Customers range from pharmaceutical companies and academic institutions to diagnostic centers and forensic labs, showcasing the broad applicability of the QIAcuity system.

Future of QIAcuity in Clinical Testing

Looking ahead, QIAGEN is poised to expand the QIAcuity platform into clinical testing. An in-vitro diagnostic variant is scheduled for launch in the fall of 2024. This version will be instrumental in diagnosing infectious diseases and monitoring cancer progression through less invasive liquid biopsies. QIAGEN is actively collaborating with pharmaceutical companies to develop companion diagnostics that leverage the platform's impressive sensitivity and accuracy.

About QIAGEN

QIAGEN N.V., based in the Netherlands, stands out as a global leader in Sample to Insight solutions. With a mission to empower customers with valuable molecular insights from their samples, QIAGEN's technologies effectively isolate and analyze nucleic acids and proteins. Targeting a diverse customer base of more than 500,000 around the world, the company continues to thrive in molecular diagnostics, life sciences, and automation solutions. As of mid-2024, QIAGEN employs over 5,900 individuals across 35 locations, signifying its robust global presence.

Frequently Asked Questions

What are the primary applications of the new QIAcuity assays?

The new assays are designed for studying cancer, genetic disorders, infectious diseases, and environmental monitoring.

How does the GeneGlobe platform enhance research capabilities?

GeneGlobe integrates pre-designed assays with an extensive database of biological entities, enabling more precise analysis and research efficiency.

What future developments can we expect from QIAGEN's QIAcuity platform?

QIAGEN is set to introduce an in-vitro diagnostic version of QIAcuity, aimed at supporting clinical applications like diagnosing diseases and monitoring cancer.

Who are the primary users of the QIAcuity digital PCR system?

The system is utilized by pharmaceutical companies, academic institutions, diagnostic centers, and forensic labs, illustrating its versatile applicability.

How many assays are currently available on the QIAcuity platform?

With the recent expansion, QIAGEN now offers over 2,300 validated assays on the QIAcuity platform.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.